SGK2
SGK2 is a serum/glucocorticoid-regulated serine/threonine kinase and an SGK isoform related to SGK1 and SGK3[1]. Mechanistically, SGK2 links PI3K-related kinase signaling with ERK1/2, AKT, GSK-3β/β-catenin, autophagy, and ferroptosis-associated GPX4 regulation in cancer models[2][3][4][5]. Compared with related SGK isoforms, SGK2 shows distinct experimental relevance in colon, renal, hepatocellular, prostate, and ovarian cancer models[2][3][4][5][6]. For research applications, SGK2 inhibition has been used to increase platinum sensitivity by blocking autophagy through impaired lysosomal acidification[6].
Références:
- [1]. Kobayashi T, et al. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J. 1999;344(1):189-197.
- [2]. Liu Y, et al. SGK2 is overexpressed in colon cancer and promotes epithelial-mesenchymal transition in colon cancer cells. Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1912-1917. [Content Brief]
- [3]. Liu Y, et al. SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation. Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2756-2767. [Content Brief]
- [4]. Liu J, et al. SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3beta/beta-catenin signaling in HCC cells. Tumour Biol. 2017;39(6):1010428317700408.
- [5]. Cheng L, et al. SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death Dis. 2023 Jan 31;14(1):74. [Content Brief]
- [6]. Ranzuglia V, et al. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells. Oncogene. 2020 Oct;39(40):6370-6386. [Content Brief]
All Product Categories
-
SGK2 Produits associés (2)
-
PT109
0 ImagesPT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease. -
loading...loading...
-
-
SGK1-IN-6
0 ImagesCat. No.: HY-170933CAS No.: 3046378-98-4SGK1-IN-6 is a selective SGK1 inhibitor with an IC50 of 0.39 μM, showing selectivity over SGK2/3. SGK1-IN-6 inhibits cancer cell migration and invasion, improves SGK1 protein thermal stability. SGK1-IN-6 decreases SGK1 protein levels in tumor tissues, suppresses tumor growth in mouse xenograft models. SGK1-IN-6 can be used for the research of prostate cancer. -
loading...loading...
-
